Visnagin

Visnagin is a furochromone compound derived from the plant Ammi visnaga that exerts organ-protective effects primarily through inhibition of pro-inflammatory cytokines and modulation of oxidative stress pathways. Preclinical research highlights its potential in protecting the kidneys and heart from chemotherapy-induced damage without compromising anticancer efficacy.

Origin & History

Visnagin is a furanochromone compound extracted from the flowers and seeds of Ammi visnaga L. (Khella), a Mediterranean plant in the Apiaceae family. It is typically obtained through aqueous extraction methods from plant material, with extracts often standardized to visnagin content.

Historical & Cultural Context

Ammi visnaga, the source of visnagin, has been used in Middle Eastern and North African traditional medicine, particularly in Unani and Arabic systems. Traditional applications included treatment of urinary disorders, kidney stones, and as a diuretic and spasmolytic agent.

Health Benefits

• Kidney protection: Reduced markers of acute kidney injury in animal models through anti-inflammatory mechanisms (Preliminary evidence - PMID: 40991986)
• Cardiovascular support: Protected against doxorubicin-induced cardiomyopathy in zebrafish and mouse models without reducing chemotherapy efficacy (Preliminary evidence - PMID: 25504881)
• Testicular health: Decreased oxidative stress and inflammation in rat ischemia/reperfusion injury models at 30-60 mg/kg doses (Preliminary evidence - PMID: 37916367)
• Anti-inflammatory effects: Suppressed inflammatory pathways including NF-κB and NLRP3 inflammasome in preclinical studies (Preliminary evidence)
• Potential anticancer properties: Demonstrated antiproliferative effects on melanoma cells through ROS-induced apoptosis in vitro (Preliminary evidence - PMID: 30694454)

How It Works

Visnagin suppresses NF-κB-mediated inflammatory signaling, reducing downstream pro-inflammatory cytokines such as TNF-α and IL-6 that drive acute organ injury. In cardiac tissue, it has been shown to inhibit mitochondrial dysfunction pathways triggered by doxorubicin, preserving cardiomyocyte viability without interfering with reactive oxygen species generation required for chemotherapeutic tumor killing. Its antioxidant activity involves upregulation of Nrf2-dependent cytoprotective enzymes, including heme oxygenase-1 (HO-1) and superoxide dismutase (SOD).

Scientific Research

No human clinical trials or RCTs were identified for visnagin; all evidence comes from preclinical animal and in vitro studies. Key studies include rat models of testicular injury (n=28, PMID: 37916367), murine acute kidney injury models (PMID: 40991986), and zebrafish/mouse cardiomyopathy models (PMID: 25504881).

Clinical Summary

Current evidence for visnagin is entirely preclinical, derived from animal models including zebrafish and rodents. In acute kidney injury models, visnagin administration reduced serum creatinine and blood urea nitrogen levels alongside decreased renal tissue expression of inflammatory markers (PMID: 40991986). Cardioprotective studies in doxorubicin-treated zebrafish and mouse models demonstrated preserved cardiac function measured by ejection fraction without attenuating tumor cell cytotoxicity. No human clinical trials have been conducted, making it premature to assign therapeutic dosages or confirm efficacy in humans.

Nutritional Profile

Visnagin is a naturally occurring furochromone (furanochromone) compound, not a conventional food ingredient, so it lacks a traditional macronutrient or micronutrient profile. It is a pure bioactive small molecule (molecular formula: C11H10O4, molecular weight: 206.19 g/mol) isolated primarily from the seeds of Ammi visnaga (toothpick weed/khella plant). As a concentrated phytochemical compound, it does not contribute meaningful calories, proteins, fats, or carbohydrates in its isolated form. Key bioactive characteristics include: furochromone scaffold conferring antioxidant and anti-inflammatory activity; structural similarity to khellin, another Ammi visnaga-derived compound; demonstrated capacity to inhibit NLRP3 inflammasome activation relevant to its kidney-protective effects. Bioavailability notes: Being a lipophilic small molecule with moderate polarity, visnagin is expected to have reasonable oral bioavailability, though specific pharmacokinetic data in humans is limited; animal studies suggest hepatic metabolism via cytochrome P450 enzymes; the compound shows good tissue distribution including cardiac and renal tissues as evidenced by experimental models. No established dietary reference intakes or nutritional concentration benchmarks exist, as visnagin is studied as a pharmacological agent rather than a dietary nutrient. Research doses in animal models typically range from 5–50 mg/kg body weight.

Preparation & Dosage

No human dosages have been established. Animal studies used 2.5-10 mg/kg orally (in rats, solubilized in 25% Captisol®) or 30-60 mg/kg intraperitoneally. Aqueous extracts of A. visnaga showed enhanced bioavailability compared to pure visnagin. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Hawthorn extract, Quercetin, N-Acetyl Cysteine, Milk thistle, Cordyceps

Safety & Interactions

No human safety data or established tolerable dose ranges exist for visnagin as an isolated supplement, as all studies to date are preclinical. Its parent plant, Ammi visnaga, contains khellin and other furochromones known to cause photosensitivity, hepatotoxicity at high doses, and gastrointestinal upset, so similar risks may apply to visnagin. Potential interactions with chemotherapy agents warrant caution, and individuals on cardiac or nephroprotective medications should avoid use without medical supervision. Visnagin should be avoided during pregnancy and lactation due to a complete absence of safety data in these populations.